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Abstract
The 2013–2015 outbreak of Ebola virus disease in Guinea, Liberia, and Sierra Leone was 
unprecedented in the number of documented cases, but there have been few published reports on 
immune responses in clinical cases and their relationships with the course of illness and severity of 
Ebola virus disease. Symptoms of Ebola virus disease can include severe headache, myalgia, 
asthenia, fever, fatigue, diarrhea, vomiting, abdominal pain, and hemorrhage. Although 
experimental treatments are in development, there are no current U.S. Food and Drug 
Administration–approved vaccines or therapies. We report a detailed study of host gene expression 
as measured by microarray in daily peripheral blood samples collected from a patient with severe 
Ebola virus disease. This individual was provided with supportive care without experimental 
therapies at the National Institutes of Health Clinical Center from before onset of critical illness to 
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recovery. Pearson analysis of daily gene expression signatures revealed marked gene expression 
changes in peripheral blood leukocytes that correlated with changes in serum and peripheral blood 
leukocytes, viral load, antibody responses, coagulopathy, multiple organ dysfunction, and then 
recovery. This study revealed marked shifts in immune and antiviral responses that preceded 
changes in medical condition, indicating that clearance of replicating Ebola virus from peripheral 
blood leukocytes is likely important for systemic viral clearance.
Introduction
During the 2013–2015 Ebola virus disease (EVD) outbreak in Guinea, Liberia, and Sierra 
Leone, the World Health Organization reported 28, 616 cases with 11, 310 deaths (1, 2). 
This outbreak, caused by a Makona variant of Ebola virus (EBOV), had an estimated 40% 
case fatality rate (3, 4).
EBOVs infect numerous cell types, including monocytes, macrophages, dendritic cells 
(DCs), endothelia, epithelia, and hepatocytes (3). Infection leads to suppression of antiviral 
responses, alterations in proinflammatory responses, and immune cell dysregulation (5, 6). 
Severe EVD in humans occurs after EBOV exposure to non-intact skin or mucosa. Clinical 
illness onset follows an average incubation of 6 days and is characterized by neuromuscular 
weakness, fever, and asthenia (7–9). High-level viremia and broad tissue tropism result in 
widespread infection (10). Complex pathogenesis due to direct viral-mediated cellular injury 
and indirect host-mediated injury contributes to multiple organ dysfunction (MOD) (11). 
Hypovolemic shock, attributable to gastrointestinal fluid losses from recurrent episodes of 
emesis and large-volume watery diarrhea, contributes to tissue ischemia and mortality (8). 
Although much has been learned about EVD in humans from this recent large outbreak, 
detailed molecular studies of EVD in humans are critical because significant gaps remain in 
our knowledge of the molecular aspects of disease and associated clinical correlates.
Here, daily global gene expression responses were measured in peripheral blood from a 34-
year-old male health care worker exposed to EBOV in Sierra Leone and evacuated to 
National Institutes of Health (NIH) on day 7 (d7) of clinical illness through onset of critical 
illness and recovery (12). This patient received supportive care without experimental 
therapies and, after recovery and viral clearance from blood, was released from the hospital 
on d33. Kinetics of gene expression were characterized using Pearson correlation and 
principal components analyses (PCAs) to identify key transition points. Gene ontology and 
pathway mapping of these major transition points, and the overall gene expression response, 
were performed to characterize host responses that correlated with EVD, including 
replication of virus in peripheral blood leukocytes (PBLs), serum viral load, coagulopathy, 
critical illness, and recovery.
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Results
PBL global gene expression response shows distinct phases correlating with viral 
replication and different stages of illness
To determine the kinetics of viral replication in PBLs and its effect on gene expression, we 
performed strand-specific quantitative reverse transcription polymerase chain reaction (qRT-
PCR) to measure both EBOV nucleoprotein (NP) mRNA as a marker of active viral 
replication and NP vRNA as a marker of presence of virions. EBOV NP mRNA was 
detected from d7 to d11, peaked at d9 [cycle threshold (Ct) = 31], and then declined to 
below detection by d12 (Fig. 1A). EBOV NP vRNA was detected from d7 to d14, peaked at 
d8 to d9 (Ct = 29), and then decreased to below detection by d15. These data showed that 
PBL EBOV replication, as indicated by the presence of NP mRNA, ceased by d12, and the 
presence of EBOV genomic RNA, as measured by NP vRNA, was cleared from PBLs by 
d15. The peak of PBL-associated EBOV NP mRNA and vRNA on d8 to d9 approximated 
the peak of serum EBOV glycoprotein (GP) RNA on d7 to d8, reported previously (12). 
EBOV RNA in PBLs peaked just before the patient was downgraded to critical condition on 
d10. The level of PBL-associated NP mRNA showed a sudden rise on d7 to d9, suggesting 
that during the start of infection, rapid replication in a small population of cells, likely 
myeloid cells, drove serum EBOV RNA to peak on d9.
Microarrays were used to measure gene expression responses in PBLs on 21 of the 26 days 
of inpatient care (d7 to d22, d24, d25, d28, d31, and d33) and 4 outpatient visits (d59, d103, 
d180, and d270). Expression values from the patient's PBL at each time point were 
compared to expression in a pool of PBL RNA from 29 healthy adult donors. This analysis 
showed that 8660 sequences were differentially expressed with at least a twofold change in 
concentration in at least 30% of time points (Fig. 1B). Pearson analysis was performed to 
understand the relationship between gene expression changes and patient's course of EVD.
A two-dimensional similarity matrix (Fig. 1C), composed of pair-wise Pearson correlation 
coefficients of gene expression levels, showed highest similarity between samples taken on 
d7 to d13 (phase 1), d14 to d21 (phase 2), d22 to d24 (phase 3), and d25 to d28 (phase 4) 
and during outpatient visits between d59 and d270 (phase 5). This analysis showed that gene 
expression responses in PBLs underwent several phases from onset of critical illness through 
recovery, generally preceding changes in clinical classification.
Gene expression differences correlated with changes in serum EBOV RNA levels
Correlation analysis was next performed using clinical data, including EBOV GP RNA in 
serum (systemic viral load), EBOV NP mRNA in PBLs (viral replication in PBLs), D-dimer 
and platelet counts (coagulopathy), and serum creatinine as a surrogate marker for critical 
illness. Pearson analysis was performed to identify host transcripts whose expression 
correlated with kinetics of serum EBOV GP RNA, with a Pearson correlation coefficient of 
≥0.6. This value was chosen to maximize our ability to identify transcripts whose expression 
levels changed in accordance with changes in serum EBOV GP RNA levels and to identify 
subtle transition points in host responses during the course of inpatient illness. Similar to 
PBL gene expression in Fig. 1C, the Pearson similarity matrix (Fig. 2A) revealed four 
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phases with three major transition points in gene expression responses that were positively 
correlated (n = 2690) and negatively correlated (n = 1071) with serum EBOV GP RNA Ct 
values (Fig. 2B). These marked transitions in gene expression profiles occurred on d13 to 
d14 (phase 1 to 2), d20 to d21 (phase 2 to 3), and d25 to d28 (phase 3 to 4).
Gene ontology mapping of positively correlated transcripts showed activation of antiviral, 
inflammatory, oxidative stress, DNA damage, cell death, and wound healing responses (table 
S1). Antiviral responses included type I interferon (IFN) signaling and pattern recognition 
receptor signaling, whereas immune and inflammatory responses included innate immune 
response markers, antigen processing, and presentation of peptide antigen via major 
histocompatibility complex (MHC) class I, response to IFN-γ, leukocyte activation, cellular 
response to cytokine stimulus, regulation of interleukin-6 production, and response to stress. 
A marked increase in expression of genes involved in response to oxidative stress and DNA 
damage was also observed, including signal transduction by p53, G1 DNA damage 
checkpoint, response to DNA damage, and activation of cell death responses, including 
apoptotic signaling, tumor necrosis factor (TNF)– mediated signaling, and regulation of 
programmed cell death, along with expression of genes involved in coagulation, wounding, 
and repair responses.
Gene ontology analysis of transcripts negatively correlated with serum EBOV GP RNA Ct 
values was dominated by repair-related pathways, including regulation of ion transport, cell-
cell signaling, anatomical structure morphogenesis, anatomical structure development, cell 
differentiation, system development, and multicellular organism development. Intriguingly, 
49% of sequences (n = 529) negatively correlated with serum EBOV GP RNA Ct values 
were unmapped using gene ontology terms (table S2).
To identify host responses underlying these transitions, we directly compared gene 
expression profiles of d13 and d14, d20 and d21, and d25 and d28 (Fig. 2, C to E). Analysis 
of individual transition points, phase 1 to 2 (d13 to d14), phase 2 to 3 (d20 to d21), and 
phase 3 to 4 (d25 to d28), revealed that different pathways dominated different transition 
points.
Gene expression correlated with host response transition on d13 to d14 of illness
To determine pathways differentiating d13 to d14, we directly compared the expression of 
transcripts positively correlated with serum EBOV GP RNA Ct values on these days. This 
analysis identified 1695 transcripts ≥1.5-fold more highly expressed on d13 relative to d14 
and 655 transcripts ≥1.5-fold more highly expressed at d14 relative to d13 (Fig. 2C). 
Ontology analysis of transcripts with higher d13 expression showed enrichment of antiviral, 
innate immune, inflammatory, reactive oxygen species (ROS), and cell death responses 
(table S3). These included type I IFN signaling, response to IFN-γ, regulation of cytokine 
secretion, respiratory burst by NADH (reduced form of nicotinamide adenine dinucleotide)–
dependent system producing hydrogen peroxide, super-oxide anions and hydroxyl radicals, 
positive regulation of nitric oxide synthase biosynthesis, regulation of TNF superfamily 
production, and regulation of endopeptidase activity involved in apoptotic signaling.
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Gene ontology analysis of transcripts with higher d14 expression was dominated by cell 
proliferation and adenosine 5′-triphosphate (ATP) biosynthesis, ubiquitin-mediated 
proteolysis, and DNA damage (including mitochondrial DNA damage), and DNA damage–
associated cell cycle arrest, nuclear factor κB (NF-κB)–inducing kinase (NIK)/ NF-κB 
signaling, and chromatin assembly (table S4). The d13 to d14 transition was also associated 
with induction of MHC class II genes in peripheral blood (fig. S1), and serum 
immunoglobulin analysis showed that Ebola- and GP-specific immunoglobulin Gs(IgGs) 
were detected starting on d13 to d14 (fig. S2).
Gene expression correlated with host response transition on d20 to d21 of illness
An identical approach was used to identify transcripts with ≥1.5-fold higher expression on 
d20 versus d21. This analysis identified 550 transcripts with higher expression on d20 and 
431 transcripts with elevated expression on d21 (Fig. 2D). Gene ontology analysis showed 
that transcripts with higher d20 expression (n = 550) were dominated by innate immune 
response markers, cytokine-mediated signaling, defense response to virus, mitotic cell cycle 
process, and regulation of protein metabolic process (table S5). In contrast, gene ontology 
analysis of transcripts with higher d21 expression showed repair, oxidative phosphorylation, 
and metabolic responses, including respiratory electron transport chain, nucleoside 
triphosphate metabolism, cellular respiration, mitochondrial ATP synthesis–coupled electron 
transport, oxidative phosphorylation, and glycosyl compound metabolism (table S6). The 
d20 to d21 transition was also associated with appearance of neutralizing antibodies (fig. 
S3), clearance of EBOV GP RNA from serum, a decrease in total PBL counts, end of renal 
and respiratory failure, and upgrading from critical to serious condition.
Gene expression correlated with host response transition on d25 to d28 of illness
The d25 to d28 transition was similarly assessed and identified 132 transcripts with ≥1.5-
fold higher expression on d25 relative to d28 (Fig. 2E). The lack of enriched biological 
processes was likely due to the small number of sequences (table S7). However, several type 
I IFN-stimulated genes (ISGs), including IFITM1, IFITM2, IFITM3, IFIT1, IFI6, and 
SOCS3, were identified. Several neutrophil function–related genes (MPO and CD177) and 
innate inflammatory response–related genes (IL1R2, LY96, MMP9, and TNFAIP6) were 
also present. Apoptosis-related genes (including DEDD2 and OLFM4) were also identified 
with higher expression on d25. Several genes (SOCS3, IL1R2, TNFAIP6, and OLFM4) are 
negative regulators of cytokine-related responses, suggesting a role in down-regulating 
inflammatory and apoptosis-related responses.
Gene ontology of sequences with ≥1.5-fold higher d28 expression (n = 1688) showed 
activation of antigen presentation–related responses and a slight reactivation of antiviral and 
inflammatory responses (table S8), although with much lower expression than was observed 
on d7 to d13 (fig. S4). These included response to type I IFN signaling, positive regulation 
of leukocyte-mediated immunity, IFN-γ–mediated signaling, antigen processing and 
presentation of exogenous peptide antigen via MHC class I, and Fc-γ receptor signaling and 
phagocytosis.
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Gene expression correlated with PBL EBOV NP mRNA levels
To characterize the effect of EBOV replication and clearance from PBLs on host gene 
expression in PBLs, we performed correlation analysis (Pearson coefficient ≥ 0.6) using 
PBL EBOV NP mRNA Ct values. This analysis identified transcripts (n = 444) with 
expression levels that correlated with PBL EBOV replication (Fig. 3A). Ontology analysis 
revealed significant enrichment for antiviral, inflammatory, and cell death–related responses 
(table S9), including type I IFN signaling, IFN-γ–mediated signaling, cytokine-mediated 
signaling, and positive regulation of programmed cell death. Cell death– and immune 
response– correlated genes included CASP1, CASP4, RIPK3, CXCL1, IL1B, IL2RG, LY96, 
and high levels of C2 (>20-fold increase at peak between d8 and13). This population was 
dominated by expression of type I ISGs that markedly decreased between d13 and d14 (Fig. 
3B). These genes included canonical ISGs, such as ADAR, IRF7, IRF9, OAS1, OAS2, 
OAS3, IFIT1, IFIT3, MX1, IFI35, IFI44, ISG15, and IFI6. Multiplex qRT-PCR was also 
performed on a subset of type I IFNs and ISGs and showed that three type I IFN genes 
(IFNB1, IFNA6, and IFNA21), cytosolic viral RNA sensor (IFIH1), and ISGs (IFI27, IFI44, 
IFI6, IFIT1, IFIT2, IFIT3, ISG15, MX1, and OAS1) were more highly expressed on d13. 
(Fig. 3C; additional qRT-PCR data in fig. S5). Transcripts with higher d14 expression were 
related to activation of lymphocytes, including IFNG and IRF4, and may represent a shift 
from an innate immune cell–dominated response on d13 to a lymphocyte-predominant 
response on d14. Direct comparison of cytokine signaling and cell death–related pathways 
on d13/d14 showed that these were similarly more highly expressed at d13 than on d14 (Fig. 
3, D and E, respectively). Thus, the transition between phases 1 and 2 was driven 
predominantly by decreased antiviral response–related gene expression and an increase in 
adaptive immune response markers.
Gene expression associated with distinct phases of innate and adaptive immune 
responses
Expression profiles of inflammatory mediators (n = 3518) were examined to identify 
immune response markers critical for controlling viral replication and mediating viral 
clearance. Of these, 1029 transcripts showed at least a twofold difference in expression 
relative to normal controls in at least four time points. A correlation matrix, composed of 
pairwise Pearson correlation coefficients of transcript expression values, demonstrated high 
similarity between samples taken on d7 to d13 (phase 1), d14 to d21 (phase 2), d22 to d24 
(phase 3), and d25 to d270 (phase 4) (Fig. 4A). These inflammation-related gene 
expression–driven phases were comparable with the phases of gene expression correlating 
with EBOV GP RNA in serum (Fig. 2A).
K-means analysis of these transcripts further identified groups of potentially co-regulated 
genes based on expression level and pattern (Fig. 4B) that generally correlated with viral 
kinetics in either PBLs or serum. Transcripts in groups I (n = 183) and II (n = 34) were most 
highly expressed from d7 to d13 (Fig. 4B). During this period, serum EBOV GP RNA levels 
peaked (d8) followed by decline (Fig. 1A). After d13, expression levels of these transcripts 
decreased but remained elevated until d25 before decreasing to near-baseline levels. During 
this period, serum EBOV GP RNA levels continued to decline until they become 
undetectable at d24. Groups I and II represent some of the most highly expressed transcripts 
Kash et al. Page 6
Sci Transl Med. Author manuscript; available in PMC 2018 April 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
at any time point and include classic antiviral response–related genes (IFIT1-3, ISG15, 
IFI27, IFI35, and IFI44) and type I and II IFN signaling (OAS2, OAS3, Mx1, IRF7, and 
IRAK3) that are likely important for attenuating viral replication. Upstream analysis 
identified key antiviral response–related transcription regulators (STAT1, STAT2, STAT3, 
and IRF1/IRF7) and multiple IFNs (IFNL1 and IFNα/β/γ) as upstream regulators (table 
S10). That expression of these transcripts remained high despite a concomitant decrease in 
serum EBOV RNA levels suggests a role in control of viral replication.
Expression of transcripts in groups III (n = 61), IV (n = 375), and V (n = 229) were 
generally consistent from d7 to d24, after which levels declined (table S10). Transcripts in 
these groups were dominated by genes involved in T and B lymphocyte responses and 
coincided with both clearance of EBOV RNA from peripheral blood and an increase in 
Ebola-specific IgG titers (figs. S2 and S3). Sequences in group III were the most highly 
expressed and remained elevated even at d270. Gene ontology analysis showed enrichment 
for lymphocyte-related functions, including April-mediated signaling, B lymphocyte 
activating factor signaling, interleukin-6 (IL-6) signaling, and granzyme A signaling. 
Further, there were genes associated with lymphocyte homeostasis/ proliferation (CD70, 
TNFRSF13B, TNFRSF17, IRF5, SOCS3, HAVCR2, and MAPK14) and protein folding/
trafficking (FKBP1A and HSPA5). Predicted upstream regulators of these sequences 
included cytokines (CD40LG, IFN-γ, TNF, IFNα, IL-2, and IL-3) and the transcription 
factor signal transducer and activator of transcription 1 (STAT1) that function in both innate 
and adaptive immune responses (table S10). Transcripts in group IV were also enriched for 
adaptive immune response functions, death receptor signaling, including the FAS pathway 
(CASP8, CASP9, CFLAR, and FADD). Consistent with death receptor signaling, there was 
enrichment of genes associated with epithelial cell death and lymphocyte development/
activation/proliferation, possibly reflective of cell-mediated immune responses targeting 
infected cells. Predicted upstream regulators of this group were consistent with T and B 
lymphocyte responses [including CD40LG, CD3, T cell receptor (TCR), IL-2, IL4, BCR, 
and IFN-γ] (table S10). Transcripts in group V also represented processes required for 
clearance of infected cells, including genes that regulate T lymphocyte development/
differentiation. In addition, neutrophil recruitment/activation (CCL3, CCL4, CD14, and 
ITGAM), ROS, and macrophage/antigen-presenting cell–related genes were enriched, 
possibly reflecting repair processes after cell-mediated tissue damage (table S10). 
Collectively, immune response–related gene expression encompassing d7 to d24 was 
dominated by T and B lymphocyte–mediated activity, coinciding with the steady decline and 
subsequent clearance of EBOV RNA from serum, likely reflective of responses critical for 
clearance of infected cells and development of protective immunity.
Groups VI (n = 95) and VII (n = 52) included transcripts with expression levels that 
increased after viral clearance from serum (Fig. 4B). Sequences in group VI showed slightly 
elevated levels until d24, at which time they increased further (table S10). Sequences in 
group VII showed decreased levels relative to controls until d24 when they increased. The 
expression level of transcripts in both groups remained elevated throughout the remaining 
time points, coinciding with patient recovery. Some genes are involved in hematopoiesis/
immune cell function, including development of pro-T lymphocytes (BB3, CD3D, IL2RB, 
CD27, Bax, and ZFPM1), recruitment of memory T lymphocytes (CCL5 and CCR10), 
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differentiation of DC (CSFIR), and Nurr77 signaling (BCL2, MEF2D, and RXRA). These 
processes may reflect renewal of homeostatic immune cell populations after viral clearance.
Total PBL numbers were elevated between d8 and d17 and again on d21 and d24, after 
which they returned to normal range (4230 to 9070 cells/μl) (Fig. 4C). At no point during 
the illness were they below normal range, although it is possible that leukopenia and 
lymphopenia (commonly described during EVD) (13, 14) occurred in this patient before d7. 
The monocyte population steadily increased beginning at d7 and was above normal range 
(300 to 820 cells/μl) between d10 and d24, peaking at d15 and then declining (Fig. 4C). The 
neutrophil population was elevated above normal range (1780 to 5380 cells/μl) from d8 to 
d25 (Fig. 4C). Lymphocytes were within normal range (1320 to 3570 cells/μl) throughout all 
but d14 to d15 when they were elevated, coinciding with clearance of NP vRNA from PBL. 
The multiple phases of increased lymphocytes in PBL possibly reflected alternating 
replenishment from lymphopoiesis and extravasation into tissues to target infected cells. 
Notably, return of all immune cell subsets to normal range also coincided with clearance of 
EBOV RNA from serum.
EVD is associated with moderate induction of key inflammatory chemokines and cytokines 
that generally peak before critical illness phase of EVD
Dysregulated cytokine production has been linked to lethal EBOV infection (13–17). The 
critical phase of illness (d10 to d19) was not associated with the highest levels of 
inflammatory mediators at either the mRNA or protein level in this patient (figs. S6 to S9). 
Increased mRNA levels of only limited inflammatory mediators were observed throughout 
the time course, and levels generally peaked before d10. The expression profiles of 
chemokines/receptors and cytokines/receptors that showed at least a twofold difference in 
expression level at one time point are represented in Fig. 5 (A and B, respectively). Of 
classical inflammatory mediators, only IL1-b mRNA was elevated relative to healthy 
controls consistently from d7 to d12. IL-15 mRNA, which is secreted by monocytes in 
response to viral infection and induces proliferation of natural killer (NK) cells (18) and 
memory CD8 T cell survival (19), was increased until d12, and its subsequent decrease was 
possibly related to clearance of EBOV NP mRNA in PBLs (Fig. 1A). The mRNAs encoding 
several other cytokines, including IL-21, IL-26, IL-32, IL-11, IL-27, and IL-17F, were 
transiently increased on isolated days. Expression levels of other cytokines that showed 
differential regulation were decreased, suggesting either suppression or absence of cells that 
express these mediators.
Chemokine mRNAs, particularly the CC class, were generally more highly and consistently 
elevated than cytokines, although many also had levels lower than controls. The levels of 
CCL3L3, CCL3, CXCL2, and CXCL1 mRNAs were generally higher at earlier time points, 
although CCL3 continued to be elevated until later time points. CCL4 mRNA levels were 
highest on d7 to d8 and d16 to d24, remaining elevated until well after viral clearance from 
serum. CCL23 mRNA levels, highly chemotactic for resting T lymphocytes and monocytes 
(20), were highest on d11 to d13, preceding an increase in peripheral lymphocyte and 
monocyte populations (Fig. 4C). CCL25 mRNA levels, thought to play a role in recruiting 
progenitor T lymphocytes to the thymus, were highest between d13 and d22, roughly 
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coinciding with critical illness, but remained elevated until d28. Levels peaked at d15 that 
corresponded to the highest PBL counts (Fig. 4C). Although not as highly induced as 
CCL25, CXCL16 mRNA peak levels also corresponded generally to the critical phase of 
illness (Fig. 5A). Transcript levels of many other chemokines (CCL15, CCL24, CCL21, 
CCL27, CXCL5, and CXCL14) were lower than normal controls (Fig. 5B), particularly 
during the presence of EBOV in serum.
Selected cytokines and chemokines present in peripheral blood were also measured by 
enzyme-linked immunosorbent assay (ELISA) (figs. S6 to S9) and generally supported 
mRNA expression data in that many classical inflammatory mediators were not induced. 
Those that were elevated typically peaked before onset of critical illness, when tissue injury 
preceding organ failure was highest. Of cytokines measured, TNFα, IL-12p70, IL-2, IL-4, 
and IL-5 (fig. S6) were not detectable above background at any time point. IL-1β was only 
detected on d7, whereas other mediators were detectable on d7 to d8/d9 (IL-13, IL-17a, and 
IFN-γ) (fig. S7). IL-8 was highest at d7, after which it decreased but remained detectable 
until d22, just before clearance of virus from serum. Similarly, IL-10 decreased significantly 
from d7 and became undetectable by d14. IL-6 levels were detectable from d7 followed by 
an increase on d9, peaking on d11 and then decreasing rapidly to low levels and becoming 
undetectable by d17. IL-7 was intermittently detectable (d7, d11, d12, d20, and d21) (fig. 
S8). Granulocyte colony-stimulating factor (G-CSF), which stimulates production of 
granulocytes (21), was highest on d7 and then decreased significantly by d8, just before an 
increase in neutrophils between d9 and 10 (Fig. 4C and fig. S9). It remained detectable at 
low levels until d22. Granulocyte-macrophage colony-stimulating factor (GM-CSF), which 
stimulates production of granulocytes and monocytes (22), showed a similar expression 
pattern, with the highest levels occurring on d7 to d8 and then decreasing until it was 
undetectable by d12 (fig. S9). This was just before a gradual increase in monocytes that 
occurred between d9 and d15 (Fig. 4C). The chemokines CCL2 (MCP-1) and CCL4 
[macrophage inflammatory protein-1 β (MIP-1β)] were both elevated to varying degrees 
(fig. S9). The levels of CCL2 were also highest on d7, decreasing on d8 but remaining 
relatively constant until becoming undetectable on d14. Levels of CCL4 were also highest 
on d7 but remained relatively high for all time points analyzed (up to d31), consistent with 
increased mRNA expression until d103 (Fig. 5A). This observation, along with 
inflammatory gene expression, suggests that some aspects of the inflammatory response 
remained stimulated well after viral clearance from serum in this patient, possibly resulting 
from maintenance of virus in immune-privileged sites such as the eye and testes (23–26).
mRNAs encoding receptors for cytokines and chemokines generally showed higher and 
more sustained expression than the ligands, particularly the cytokine and CXC class of 
chemokine receptors (Fig. 5, A and B). Whereas some cytokine receptors (IL11RA, IL9R, 
IL7, IL17RE, IL15RA, CXCR5, and CXCR7) showed decreased expression, many were 
highly expressed over multiple days, including components of the IL-1 receptor (IL1R2, 
IL1RN, and IL1R1), IL-18 receptor (IL18R1 and IL18RAP), and others (IL17RA, IL15RA, 
IL10RB, IL4RB, IL6RA, IL21R, IL2RB, and IL2RA). Transcripts of many chemokine 
receptors, including CCR1, CCR2, CCRL2, CCR5, CXCR1, CXCR3, and CXCR6, were 
also highly expressed over multiple time points, whereas others showed decreased 
expression (CCR3, CCR7, CXCR5, and CXCR7). Because chemokine/cytokine receptors 
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are commonly expressed on immune cells, the general lack of high levels of CXC 
chemokine/cytokine mRNAs may be more related to dysregulated immune cell function than 
the absence of specific immune cell subsets.
Gene expression underlying clinical markers of coagulopathy suggest viral-mediated 
death of macrophages, neutrophil activation, and increased phagocytosis of immune cells 
during active viral replication
Perturbations in coagulation have been observed during EVD (27–29). Abnormal platelet 
levels, D-dimer (fibrin degradation product), and aPTT (activated partial thromboplastin 
time) occurred between d7 and d15, consistent with coagulopathy previously described in 
this patient (12). Specifically, D-dimer levels were elevated (>20 μg/μl) from at least d7, 
returning to normal levels (5 μg/μl) around d16 (Fig. 6A). Platelet counts remained below 
normal levels (lower limit of normal ∼150,000/μl) until d16, increased to almost 500, 000 at 
d20, and then declined but remained within normal range through d33 (Fig. 6A).
D-dimer and platelet levels throughout the illness were used as reference profiles to identify 
transcripts whose expression level correlated with clinical parameters of coagulopathy to 
better understand underlying pathological processes. Correlation analysis (≥0.6) identified 
112 and 1516 transcripts that negatively and positively correlated with D-dimer levels, 
respectively, between d7 and d33 and were also twofold differentially expressed in at least 
four time points (fig. S10 and tables S11 and S12). Similarly, 1060 and 56 transcripts were 
identified that negatively and positively, respectively, correlated with platelet levels between 
d7 and d33 (fig. S11 and tables S13 and S14). Not surprisingly, there was significant overlap 
in transcripts that showed positive correlation with D-dimer and negative correlation with 
platelet levels (n = 1060) (table S15). Expression profiles of these transcripts, along with D-
dimer and platelet levels, are shown in Fig. 6A. Most showed elevated expression levels that 
decreased parallel to D-dimer levels decreasing and platelet levels increasing. These likely 
represent cellular processes that were being attenuated after resolution of coagulopathy, 
although they generally remained elevated to some degree beyond clinical resolution of 
coagulopathy at d15.
Gene ontology analysis of these 1060 transcripts revealed enrichment for genes associated 
with innate immune responses including macrophage/monocyte- and neutrophil-related 
activities (Fig. 6, B and C). Specifically, expression of classic antiviral response genes 
(including IFIT1, IFIT2, IFIT3, IFITM1, IFITM2, OAS1, OAS2, STAT1, and MX1) and 
neutrophil recruitment/degranulation (CXCR1, CXCR2, and others) was increased 
coincident with elevated D-dimer and depleted platelet levels (Fig. 6C). Genes involved in 
macrophage recruitment (including IL1b, CCR1, and ITBG2), death (including 
inflammasome-related NLRC4 and AIM2), and phagocytosis/engulfment of cells also 
correlated with clinical parameters of coagulopathy (Fig. 6C). One possible explanation for 
these gene expression changes is that coagulopathy results from viral replication and 
associated cytopathic effect in macrophages and DCs. Subsequent engulfment of infected 
cells by macrophages and neutrophils may then induce fibrin clot formation, possibly via 
activated neutrophils mediating thromboinflammatory injury. The decrease in D-dimer levels 
between d13 and d14 coincided with both clearance of EBOV NP mRNA from PBL by d12 
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(Fig. 1A) and significant attenuation of antiviral response gene expression, with resolution 
of coagulopathy occurring at d15.
Critical phase of illness characterized by decreasing serum EBOV RNA levels and 
transitions in lymphocyte, cell death, and organ repair–related gene expression
The patient's clinical condition deteriorated from serious to critical on d10 to d19, after 
which it was upgraded back to serious (12). This period reflected MOD associated with 
EVD. These transition points correlated closely with serum creatinine levels, which began 
rising at d10, peaked at d15, and returned to normal levels by about d20 (Fig. 7A). 
Therefore, creatinine levels were used as a surrogate marker of transitions to and from 
critical illness. Transcripts with expression kinetics correlating with serum creatinine levels 
were identified to gain insight into possible pathological processes underling the critical 
phase of illness.
Expression profiles of 420 transcripts (table S16) showed a negative correlation with 
creatinine levels and also a twofold difference in expression level compared to healthy 
controls across at least three sample times (Fig. 7A). Most showed similar or slightly 
decreased levels relative to healthy controls from d7 to d10, followed by a general decrease 
until d14/d15, after which they returned to near baseline. A subset of these transcripts 
showed increased expression relative to healthy controls on d7 to d10, followed by 
decreased expression between d11 and d20, and subsequent return to increased levels 
relative to healthy controls (Fig. 7A).
Gene ontology analysis of these transcripts showed enrichment for lymphocyte-related gene 
expression including recruitment, development, differentiation, proliferation, and activation 
of lymphocytes (Fig. 7B). Expression levels of certain lymphocyte activation markers 
(FasLG, granzyme K, and ICOS), NK markers (KLRB1, KLRC3, and KLRD1), and T 
lymphocyte markers (CD3D, CD83, CD8A, CD8B, and IL2RB) generally decreased from 
d9 to d14/d15 and then began to increase until d18/d19 (fig. S12). In contrast, total 
lymphocyte counts began increasing at d13 and peaked at d15 before decreasing again (Fig. 
4C), suggesting that a subset of lymphocytes was leaving the periphery through either 
apoptosis, as suggested by positive activation Z score for lymphocyte apoptosis (Fig. 7B), or 
extravasation into tissues. Serum EBOV RNA level was continually dropping during this 
phase (Fig. 1A), possibly as a result of cell-mediated immune responses targeting infected 
tissue. EBOV is known to have a broad tissue tropism (3, 11), resulting in direct virally 
mediated cytopathology and MOD. Organ injury leading to MOD was reached by d9/d10, 
manifested by rising serum creatinine, down-trending but elevated hepatic enzymes, and 
onset of respiratory failure (12). A transition to organ recovery was observed by d14/d15, 
manifested by decreasing creatinine and normalization of hepatic enzymes and serum 
creatinine phosphokinase levels. Cytotoxic T lymphocyte responses during this period of 
critical illness likely contributed to viral clearance from tissues tipping the balance toward 
tissue repair and recovery. This hypothesis is supported by the observation that 
inflammation-related gene expression during this phase was dominated by adaptive immune 
response markers and decreasing EBOV RNA levels (Fig. 4B).
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Positively correlated transcripts (n = 576) (table S17) generally showed slightly elevated 
levels relative to healthy controls and began increasing at d10 parallel to serum creatinine 
levels, peaking at d15 followed by gradual decrease, although they still generally remained 
slightly elevated. Gene ontology analysis of these transcripts shows increased activity (based 
on positive activation Z score) of numerous processes associated with tissue repair/recovery, 
including cell survival, development/proliferation of endothelial cells and angiogenesis 
(BMP6, ANG, GAS6, NCOA3, EDF1, PDCL3, PLOD3, SCARB1, and CLIC4), and 
epithelial tissue development (Fig. 7B). Processes predicted to be decreased based on 
expression level at d15 include organ death, apopto-sis, and necrosis (Fig. 7B).
The immune-related genes were dominated by antiviral responses and adhesion/activation 
(CD36, ITGB1, CCR2, and MIF) of antigen-presenting cells including macrophage/
monocytes (Fig. 7B). There was also enrichment of genes related with proliferation and 
adhesion of immune cells (including IL27RA, CCR2, and CXCR3) and phagocytosis/ 
engulfment of cells (ClQA, CD36, Syk, Tusc2, and GAPVD1), possibly due to clearance of 
apoptotic bodies resulting from lymphocyte targeting of infected cells. In support of this, 
enriched pathways included the unfolded protein response (including ATF6, DNAJC3, 
HSP90B1, and HSPA5) and NRF2-mediated oxidative stress response (such as DNAJC3, 
DNAJC10, GSTP1, GSK3M, and TXNRD1) (fig. S13). Genes associated with oxidative 
phosphorylation, the predominant mechanism used by lymphocytes to fuel their effector 
functions (30), were also overrepresented and included ATP5G1, COX6B1, and numerous 
genes encoding NADH–ubiquinone oxidoreductase subunits (NDUFA3, NDUFB7, 
NDUFB11, NDUFS1, NDUFS7, NDUFS8, and NDUFV3) (fig. S13).
Collectively, these data suggest that the critical phase of illness was associated with 
declining serum EBOV RNA levels, possibly related to cell-mediated immune responses 
targeting infected tissues, and increasing activation of organ repair processes. Further, peak 
expression of these genes at d15 suggests that it represented a key transition point in patient 
illness when underlying cellular processes shifted from cellular/ tissue damage to organ/
endothelium repair. d15 also corresponded to both peak serum creatinine levels and 
peripheral lymphocyte counts and clearance of EBOV NP vRNA from PBL (Fig. 1A). 
Subsequent decreasing levels of tissue repair–related gene expression likely reflected 
attenuation of these responses, as viral/immune response–mediated tissue damage was 
reduced after viral clearance along with reparative processes in tissues and organs.
To understand the complexity of EVD in this patient, a plot integrating PBL gene 
expression, antibody responses, and clinical symptoms (12) is shown in Fig. 8. Daily global 
gene expression responses were spatially arranged into a two-dimensional coordinate system 
using values from Eigen rows 1 and 2 derived from PCA of the gene expression data from 
d7 through recovery and outpatient sampling. The timing of major clinical symptoms, 
including diarrhea, fever, coagulopathy, and MOD, is overlaid. Diarrhea occurred during 
peak serum and PBL EBOV RNA, as well as type IIFN responses. Virus-specific IgMs were 
already present at low levels at d7 (fig. S14) and the appearance of GP-specific and whole-
virus IgG around d14; neutralizing antibodies were not detected until after d21. During 
recovery, “flare-ups” of PBL gene expression responses on d59 and d103 were observed; 
however, these later samples were PCR-negative for GP RNA (fig. S15).
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Discussion
Molecular correlates of disease severity, symptoms, and outcome during human EBOV 
infection are just beginning to be elucidated. A large-scale study of T lymphocyte responses 
in EVD cases during the 2013-2015 epidemic demonstrated differences in T lymphocyte 
activation between survivors and fatalities (17). Specifically, increased expression of 
inhibitory molecules CTLA-4 and PD-1 by CD8+ and CD4+ T cells correlated with greater 
inflammatory responses and fatal infections. Kinetics and amplitude of viral replication have 
also been shown to be an important factor in fatal versus nonfatal EVD (31–33). A report 
demonstrated that patients with a qRT-PCR Ct of <24 had a 22% survival rate compared 
with 87% survival in patients with Ct of ≥24 (34). Similarly, a study of seven patients with 
EVD provided supportive care and different therapeutic interventions showed that more 
severe disease was associated with increased viremia and higher expression of 
proinflammatory- and coagulopathy-related biomarkers and decreased type I IFN responses 
(29).
Whereas expression of many proinflammatory cytokines and chemokines in this patient did 
not peak until later in infection, expression of CCL3 (MIP-1α) peaked on or before d7, 
suggesting the critical role of macrophage infection during early phases of EVD noted 
previously (35, 36). The highest expression of several ISGs and the antiviral gene RSAD2 
(viperin) occurred on the first day of PBL RNA sampling (d7) and then decreased, whereas 
PBL EBOV NP mRNA increased through d9. EBOV NP mRNA and vRNA levels peaked in 
PBLs at about d9 and then were no longer detected on d12 and d15, respectively, and 
correlated with the marked decrease in type I IFN responses starting d14. This suggests that 
expression of these genes was responsible, at least in part, for clearance of virus from PBLs, 
along with virus-specific IgM already present at low levels at d7 and the appearance of GP-
specific and whole-virus IgG around d14; neutralizing antibodies were not detected until 
after d21. Activation of ROS, DNA damage, and macrophage cell death responses were also 
highest during d7 to d13, but were not associated with concomitant loss of monocytes, but 
rather an increase in monocytes peaking on d15. It is unclear whether clearance of EBOV 
from PBLs was related to death of infected macro-phages, previously described in non-
human primates (37), or if macrophages were able to halt viral replication without 
undergoing death. d13 to d15 also marked the transition from an innate immune-dominated 
to an adaptive immune-dominated response. Although liver dysfunction first appeared in this 
patient before d7, and transition from tissue injury to repair occurred by d14/d15, features of 
MOD in this patient persisted through d21 (12). The clinical grade of this patient was still 
serious, but d21 marks a further transition in the equilibrium between damage and repair 
responses that coincided with detection of neutralizing antibodies. Recovery in this patient 
was marked by an overall decrease in infection-correlated gene expression responses that 
persisted from discharge on d33 through d270, with observed flare-ups of PBL gene 
expression responses on d59 and d103; however, these later samples were PCR-negative for 
GP RNA. These data are compatible with recent studies showing persistent EBOV infection 
in immune-privileged sites and prolonged recovery from EVD (23, 38–41). McElroy et al. 
(29) also found evidence of robust T lymphocyte responses during EBOV infection, with 
sustained activation of CD8 T lymphocytes long after clearance of virus from serum, 
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suggesting continued antigen stimulation (11). However, these flare-ups could also indicate 
exposure to other community-acquired viruses during outpatient sampling.
Although this patient had critical care support and recovered from EVD, severity of MOD 
suggests a fatal outcome if care was provided in a more resource-limited setting. The peak 
serum creatinine levels in this patient were consistent with those observed during fatal EVD 
(27). Moreover, plasma levels of some cytokines/chemokines were generally more 
consistent with levels reported for fatal cases (27). A patient evacuated from Sierra Leone to 
Germany for treatment showed a similar disease course, where clinical condition 
deteriorated after peak viral load and just before a significant drop in serum viral titers. This 
also correlated with a rise in PBL and creatinine levels (42).
Excessive cytokines, lymphocyte apoptosis leading to immuno-suppression, and absence of 
antiviral IFN response have all been suggested to play a role in fatal EVD (13, 14, 16, 17). 
Ruibal et al. (17) reported that plasma levels of selected cytokines (including TNF, IL8, 
MIP-1α, and MIP-1β) were significantly higher in fatal EVD than in patients who survived. 
A study of 42 nonsurvivors and 14 survivors from five separate EVD outbreaks found that 
fatal outcomes were associated with hypersecretion of numerous proinflammatory cytokines 
(14). Similarly, analysis of samples from the 2000 outbreak of Sudan virus in Uganda found 
that levels of IL-6, IL-8, IL-10, and MIP-1b, but not IL-1B, IP10, or RANTES, were higher 
in patients with fatal infections (15). Surprisingly, but similar to the current patient, levels of 
TNF and IFN-γ were not generally increased compared to control patients (15). Although 
differences in cytokine levels were considered statistically significant in some cases, there 
was extensive variation in the levels among patients and sampling time with respect to 
clinical course was generally not reported. Serum cytokine/chemokine levels measured in 
the patient here were more consistent with levels reported for fatal cases but peaked several 
days before onset of critical illness. Furthermore, TNF, a key proinflammatory cytokine, was 
undetected in the serum, whereas IL-1β was only detected on d7. Because physiological 
effects of cytokines are rapid and short-lived, with transcriptional responses typically 
peaking within hours (43, 44), it is unclear what direct role, if any, they play in pathological 
events underlying critical illness.
Leukopenia has been reported in some cases of EVD (13, 16, 45, 46) and has been 
correlated with severity of infection (13). Despite the severity of the infection in the current 
patient, from d8, PBL populations were either within normal range or slightly elevated. 
Lymphocytes were at lower range of normal at d7 and then increased, suggesting early 
depletion and then recovery of this subset, with highest levels corresponding to critical phase 
of illness. Gene ontology analysis of transcripts with expression kinetics corresponding with 
serum creatinine levels, a surrogate marker for critical illness, predicted a decrease in 
lymphocyte activity and increase in lymphocyte apoptosis based on decreased expression 
levels of specific lymphocyte-related gene expression.
Lymphocyte apoptosis has been proposed as a cause of leukopenia during EVD (13, 14). 
Elevated CD95 expression in T lymphocytes was reported to be responsible for massive 
lymphocyte apoptosis, although no direct measurement of apoptosis was performed (14). 
However, CD95 exerts both pro- and anti-apoptotic signaling and modulates TCR/CD3-
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driven signal initiation in a dose-dependent manner, with a high dose of CD95 agonist 
(including CD95L) silencing T cells through blocking early TCR-driven induction, whereas 
a lower dose of agonist actually augments lymphocyte activation/proliferation (47). Elevated 
CD95 levels on lymphocytes may therefore not always be indicative of apoptosis. Sanchez et 
al. (13) reported that fatal cases of EVD have reduced numbers of peripheral activated CD8+ 
T lymphocytes compared to survivors. However, these patients also had much higher levels 
of serum EBOV RNA, and decreased circulating T lymphocyte populations could result 
from these cells infiltrating infected tissues. Extensive lymphocyte apoptosis as a cause of 
the decreased expression of T lymphocyte–specific genes cannotberuled outinthe current 
patient becauseno direct measurementofapoptosis was conducted. However, changes in 
peripheral lymphocyte numbers and decreasing serum viral levels suggest a subset of 
lymphocytes leaving the PBL pool and targeting infected tissue. This scenario would also 
result in decreased abundance of lymphocyte-specific gene expression in peripheral blood. 
The question of apoptosis versus tissue infiltration is difficult to answer without analyses of 
infected tissues.
This study was limited to a detailed characterization of daily changes in PBL gene 
expression responses in a single patient from early symptomatic disease to critical illness 
and through recovery. While adding to our understanding of this patient's disease, it remains 
to be shown how it applies in the larger context of human EVD, including both survivors and 
fatalities. Nonetheless, it highlights the benefits of supportive medical care, as well as the 
need to perform larger host response studies. Although we observed similarities between this 
patient and studies in nonhuman primates (48–52), we also identified several important 
differences such as a lack of a pronounced “cytokine storm” and absence of pronounced 
lymphopenia during peak illness in this patient. Improving our ability to reduce severity and 
high mortality rates of EVD will increasingly rely on studies that integrate critical care 
medicine and detailed, longitudinal host response studies in both humans and nonhuman 
primates.
Materials and Methods
Study design
Daily blood samples were collected during inpatient care of an individual infected with 
EBOV beginning before critical illness and continuing through recovery. Global expression 
of RNA isolated from PBLs in these samples was measured by expression microarray. Each 
RNA sample was labeled and hybridized in duplicate on individual arrays (n = 2). All 
samples (except for d25 and d180) were analyzed by microarray twice (n = 4). Expression 
data were correlated with other clinical information, including viral RNA concentration by 
qRT-PCR, EBOV-specific antibodies by ELISA and PRNT80 assays, and D-dimer, platelet, 
and serum creatinine measured using standard clinical microbiology laboratory methods. 
The study was not blinded.
Patient information
Blood samples from the EBOV-infected patient (clinicaltrials.gov identifier NCT02363322) 
and healthy volunteers (clinicaltrials.gov identifier NCT0138664) were obtained under 
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clinical protocols approved by the National Institute of Allergy and Infectious Diseases 
(NIAID) Institutional Review Board and were conducted in accordance with provisions of 
the Declaration of Helsinki and good clinical practice guidelines. The clinical case of this 
patient was previously described (12).
RNA isolation and expression microarray analysis
Total RNA was isolated from whole blood using PAXgene Blood RNA Kit IVD (Qiagen) 
and resuspended in TRIzol LS before removal from BSL-4 under supervision of the 
Biosurety Program of the NIH and in accordance with Division of Select Agents and Toxins 
at the Centers for Disease Control and Prevention. RNA quality was assessed using 
Bioanalyzer (Agilent Technologies). Gene expression profiling was performed using Agilent 
Human Whole Genome 44K microarrays. Fluorescent probes were prepared using Agilent 
QuickAmp Labeling Kit. Each RNA sample was labeled and hybridized in duplicate on 
individual arrays (n = 2) except for d25 and d180. Spot quantitation was performed using 
Agilent's Feature Extractor software, and data were entered into the custom database 
SLIMarray (http://slimarray.systemsbiology.net) and uploaded into Genedata Analyst 9.0 
(Genedata). Complete MIAME-compliant (53) microarray data set has been deposited in the 
National Center for Biotechnology Information (NCBI)'s Gene Expression Omnibus (GEO) 
(54) and is accessible at GEO GSE93861. TIBCO Spotfire Analyst 6.0 was used for analysis 
and heatmap creation.
WBC counts
WBC differential counts were performed at NIH Clinical Center by the Department of 
Laboratory Medicine using standard methods.
Quantitative EBOV and EBOV GP IgG ELISA
Serum samples and EBOV-specific IgG reference standard were serially diluted and 
quantified using horseradish peroxidase-labeled anti-human IgG secondary antibody (KPL). 
Detailed methods are in the Supplementary Materials.
EBOV IgM end titer ELISA
Serum samples were added to ELISA plates coated with irradiated whole EBOV antigen, as 
described in (55). Detailed methods are in the Supplementary Materials.
Plaque reduction neutralization titration assay
Serially diluted serum was mixed and incubated with 100 plaque-forming units of EBOV, 
and percent neutralization was determined relative to wells treated with media alone, as 
described in (55). Detailed methods are in the Supplementary Materials.
Quantitative cytokine analysis by Bio-Plex assay
Multiplex cytokine analysis was completed for serum samples using a magnetic bead–based 
Bio-Plex Pro Human Cytokine 17-plex Assay kit (Bio-Rad) and FLEXMAP 3D instrument 
(Luminex Corporation). Concentration of each sample analyte was determined using 
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standard curves and reported as picograms per milliliter. Normal human serum (Sigma-
Aldrich; catalog #H4522) was used as a negative control.
Quantitative reverse transcription polymerase chain reaction
Reverse transcription of equivalent amounts of total RNA was performed using SuperScript 
III First-Strand Synthesis System (Life Technologies Inc.). Primers for Ebola NP vRNA 
were as follows: forward, 5′-TCATGCGTACCAAGGAGATTAC-3′; reverse, 5′-
GCTTCACTCCATCACACTTCT-3′; probe, 5′-TCAAGTATTTGGAAGGGCACGGGT-3′. 
Primers for Ebola NP mRNA were as follows: forward, 5′-
GCGTTAAGCCACAGTTATAGCC-3′; reverse, 5′-
GGGCAGGCTAGTAGGTAAGTTAT-3′; probe, 5′-
TGGTAACTCAATATCTTAGCCAGCGA-3′. qRT-PCR was performed in duplicate using 
an ABI QuantStudio 6 Flex Real-Time PCR system.
Statistics
Data normalization was performed in Genedata Analyst using central tendency followed by 
relative normalization using pooled RNA isolated from blood of healthy volunteers (n = 29) 
as a reference. Statistical analysis was performed using individual replicates. Pearson and 
PCA were performed using Genedata Analyst 9.0. For Pearson correlation analysis, r ≥ 0.6 
was used. For visualization, values from replicates were combined using arithmetic mean. 
Ingenuity Pathway Analysis, Panther (56, 57), and Entrez Gene (www.ncbi.nlm.nih.gov/
gene) were used for gene ontology and pathway analysis using Bonferroni correction.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Overall gene expression profile in peripheral blood shows distinct phases during EVD and 
recovery
(A) Kinetics of EBOV NP mRNA and vRNA in PBLs as measured by strand-specific qRT-
PCR during course of illness. Serum EBOV GP RNA qRT-PCR data previously published in 
(12) are shown for comparison with PBL replication. (B) Heatmap showing expression 
levels of genes (n = 8660 sequences) that showed ≥2-fold change in expression level in at 
least 30% of time points relative to a pool of 29 healthy adult volunteers. For all figures, 
each heatmap column represents gene expression data from a microarray experiment 
comparing patient peripheral blood at individual time points relative to pooled RNA isolated 
from peripheral blood from healthy volunteers (n = 29). Genes shown in red were increased, 
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genes shown in blue were decreased, and genes in black indicate no change in expression in 
EVD patient relative to healthy volunteers. (C) Pairwise Pearson correlation coefficient 
similarity matrix of expression values of these 8660 sequences. *Previously reported in (12).
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Fig. 2. Gene expression correlating with kinetics of serum EBOV load
(A) Pairwise Pearson correlation coefficient similarity matrix of expression values of 
transcripts positively correlated (≥0.6) with EBOV GP RNA levels. (B) Heatmap showing 
overall expression level of genes with positive (n = 2690 sequences) or negative (n = 1071 
sequences) correlation with serum Ebola GP RNA (12). (C) Scatterplot showing relative 
expression of genes at d13/d14. Red points indicate sequences with higher expression on 
d13 (n = 2350), and blue points indicate sequences with higher expression on d14 (n = 655). 
(D) Scatterplot showing relative expression of genes at d20 and d21. Red points indicate 
sequences with higher expression on d20 (n = 550), and blue points indicate sequences with 
higher expression on d21 (n = 431). (E) Scatterplot showing relative expression of genes at 
d25/d28. Red points indicate sequences with higher expression on d25 (n = 132), and blue 
points indicate sequences with higher expression on d28 (n = 1688).
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Fig. 3. Gene expression associated with Ebola viral replication in PBLs
(A) Quantification of EBOV NP mRNA (qPCR Ct) in PBLs and heatmap showing 
expression of genes with positive correlation (≥0.6) with PBL EBOV NP mRNA. (B) 
Heatmap showing expression levels of key ISGs. (C) Graph showing relative expression of 
selected ISGs from (B) as determined by qRT-PCR. (D) Scatterplot showing relative 
expression of cytokine signaling–related genes (n = 51) at d13/d14. (E) Scatterplot showing 
relative expression of cell death–related genes (n = 29) at d13 and d14. Red points indicate 
sequences with higher expression on d13, and blue points indicate sequences with higher 
expression on d14.
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Fig. 4. Distinct phases of innate antiviral and adaptive immune response markers during EVD
Analysis of inflammation-related gene expression (n = 1029 transcripts) with ≥2-fold change 
in expression level in at least four individual time points. (A) Pairwise Pearson correlation 
coefficient similarity matrix of expression values of these transcripts. (B) Heatmap showing 
expression of innate antiviral and adaptive immune response markers. (C) Total white blood 
cell (WBC) count and differential analysis of immune cell populations.
Kash et al. Page 26
Sci Transl Med. Author manuscript; available in PMC 2018 April 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 5. Strongest induction of inflammatory mediators and receptors generally occurred during 
early EVD
Heatmaps depicting expression levels of mRNAs encoding chemokines/receptors (A) and 
cytokines/receptors (B) during EVD and recovery. Gray indicates that the sequence was not 
detected.
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Fig. 6. Gene expression correlating with clinical parameters of coagulopathy during EVD
(A) Serum D-dimer (μg/ml, left axis) and platelet levels (K/μl, right axis) and heatmap 
showing expression profiles of transcripts (n = 1016) with expression levels that are 
correlated positively with serum D-dimer levels (≥.6) and negatively with platelet levels 
(≤-0.6). (B) Gene ontology analysis of transcripts, with expression levels correlating with 
serum D-dimer and platelet values (activation Z score is based on d10 expression values). 
(C) Expression profiles of transcripts involved in macrophage recruitment, neutrophil 
recruitment, antiviral response, macrophage cell death, degranulation, and phagocytosis.
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Fig. 7. Gene expression correlating with the critical phase of EVD
(A) Serum creatinine values (U/liter, left axis) and EBOV GP levels (qPCR Ct, right axis), 
with heatmap showing expression profiles of transcripts with positive (≥0.6, n = 576) or 
negative (≥−0.6, n = 420) correlation with serum creatinine levels. (B) Gene ontology 
analysis of transcripts, with expression levels correlating with serum creatinine values 
(activation Z score is based on d15 expression values).
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Fig. 8. Model of patient host responses and clinical disease
PCA-derived model of patient PBL gene expression responses during illness course and 
recovery. Day of illness is indicated by numbered circles colored by patient medical grade 
and spatially arranged using Eigen row coordinates. (A) Host defense and immune response 
markers correlated with peak viral load and clearance of replicating virus from PBL on d7 to 
d13. (B) Activation of T lymphocytes and switch toward adaptive immune responses 
associated with appearance of Ebola GP–specific IgG and declining serum EBOV RNA 
levels on d14 to d15. (C) Continuation of adaptive immune responses and appearance of 
virus-specific IgGs correlated with decreasing serum EBOV RNA and increased mitogenic 
and metabolic responses on d16 to d20. (D) Adaptive immune and repair responses 
associated with appearance of neutralizing antibodies and clearance of serum EBOV RNA 
on d21 to d24. (E) Similarity of PBL gene expression before patient discharge on d25 to d33 
and continuing in outpatient samples on d59 to d270. Timing of clinical symptoms (co-
agulopathy, diarrhea, fever, and MOD) is shown as reported in (12).
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